Gabather AB (publ) (GABA) - Total Liabilities

Latest as of March 2026: Skr4.20 Million SEK ≈ $451.45K USD

Based on the latest financial reports, Gabather AB (publ) (GABA) has total liabilities worth Skr4.20 Million SEK (≈ $451.45K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GABA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Gabather AB (publ) - Total Liabilities Trend (2014–2025)

This chart illustrates how Gabather AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Gabather AB (publ) (GABA) total assets.

Gabather AB (publ) Competitors by Total Liabilities

The table below lists competitors of Gabather AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
SPoT Coffee Ltd
V:SPP
Canada CA$9.36 Million
Digital Ally Inc
NASDAQ:DGLY
USA $17.56 Million
Camellia Plc
LSE:CAM
UK GBX128.80 Million
Northern 3 Vct Plc
LSE:NTN
UK GBX196.00K
KATORO GOLD PLC LS-01
F:622
Germany €120.20K
AnalytixInsight Inc
V:ALY
Canada CA$1.93 Million
Goldcliff Resource Corp
V:GCN
Canada CA$1.03 Million
Lord Resources Ltd
AU:LRD
Australia AU$191.42K

Liability Composition Analysis (2014–2025)

This chart breaks down Gabather AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Gabather AB (publ) (GABA) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.66 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.49 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.60 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gabather AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gabather AB (publ) (2014–2025)

The table below shows the annual total liabilities of Gabather AB (publ) from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 Skr4.69 Million
≈ $505.04K
-21.89%
2024-12-31 Skr6.01 Million
≈ $646.56K
-12.65%
2023-12-31 Skr6.88 Million
≈ $740.18K
+107.54%
2022-12-31 Skr3.31 Million
≈ $356.64K
-25.16%
2021-12-31 Skr4.43 Million
≈ $476.52K
+33.74%
2020-12-31 Skr3.31 Million
≈ $356.32K
+33.70%
2019-12-31 Skr2.48 Million
≈ $266.50K
+7.99%
2018-12-31 Skr2.29 Million
≈ $246.80K
-5.22%
2017-12-31 Skr2.42 Million
≈ $260.38K
+55.05%
2016-12-31 Skr1.56 Million
≈ $167.93K
+114.55%
2015-12-31 Skr727.31K
≈ $78.27K
+38.47%
2014-12-31 Skr525.26K
≈ $56.53K
--

About Gabather AB (publ)

ST:GABA Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$1.76 Million
Skr16.36 Million SEK
Market Cap Rank
#30241 Global
#689 in Sweden
Share Price
Skr0.03
Change (1 day)
+0.75%
52-Week Range
Skr0.02 - Skr0.06
All Time High
Skr71.87
About

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more